Showing 2 of 10 years of data. Sign up free for 5 years of history.
View PlansJenburkt Pharma (JENBURKT) reported revenue of ₹1.52B in FY2025 with net income of ₹320.61M. Total assets stood at ₹1.96B and free cash flow was ₹81.92M.
Jenburkt Pharma Income Statement
Hover the chart icon for year-over-year change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1.42B | 1.52B | |
| Cost of Rev. Cost of Revenue | -304.11M | -296.57M | |
| Gross Profit | 1.12B | 1.22B | |
| SGA Sales, General & Admin | -424.89M | -455.36M | |
| Op. Income Operating Income | 307.80M | 376.65M | |
| PBT Profit Before Tax | 351.76M | 439.33M | |
| Net Income | 259.77M | 320.61M | |
| Dil. Shares Diluted Shares | 4.41M | 4.41M | |
| Diluted EPS | 58.86 | 72.65 |
Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.
Understanding the Income Statement
The income statement shows Jenburkt Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.
Jenburkt Pharma Balance Sheet
Hover the chart icon for year-over-year change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Curr. assets Total current assets | 1.10B | 565.32M | |
| Non-curr. assets Total non-current assets | 553.72M | 1.40B | |
| Total assets | 1.65B | 1.96B | |
| Curr. liabilities Total current liabilities | 163.79M | 188.19M | |
| Non-curr. liab. Total non-current liabilities | 37.80M | 55.90M | |
| Total liabilities | 201.59M | 244.09M | |
| Total equity | 1.45B | 1.72B | |
| Total liab. & eq. Total liabilities & equity | 1.65B | 1.96B |
Figures in ₹ — millions (M), billions (B), trillions (T).
Understanding the Balance Sheet
The balance sheet captures Jenburkt Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.
Jenburkt Pharma Cash Flow Statement
Hover the chart icon for year-over-year change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 259.77M | 320.61M | |
| Operating CF Cash flow Operating Activities | 81.24M | 279.06M | |
| Capex Investments in PPE | -25.54M | -197.14M | |
| Investing CF Cash flow Investing Activities | -5.80M | -170.45M | |
| Dividend Paid | -63.18M | -67.81M | |
| Financing CF Cash flow Financing Activities | -70.78M | -76.22M | |
| Cash (start) Cash at beginning of period | 36.60M | 41.25M | |
| Cash (end) Cash at end of period | 41.25M | 73.65M | |
| FCF Free Cash Flow | 55.70M | 81.92M |
Figures in ₹ — millions (M), billions (B), trillions (T).
Understanding Cash Flow
The cash flow statement tracks how Jenburkt Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025
Now find out what Jenburkt Pharma is worth
You've seen the statements. A paid plan turns those numbers into a verdict — fair-value estimates, undervalued-stock screening, and ownership signals.
- Fair value from 5 models — DCF, DDM, P/E, P/B & EPS growth
- Undervalued-stock screener across 500+ companies
- Insider trades, bulk deals & promoter shareholding trends
Related Stocks
Caplin Point (CAPLIPOINT)
Revenue grew 15.5% to ₹2,034 Cr in FY2025.
Jubilant Pharmova (JUBLPHARMA)
Revenue of ₹7,291 Cr in FY2025.
Strides Arcolab (STAR)
Turned profitable with net income of ₹3,598 Cr in FY2025.
Biocon (BIOCON)
Revenue compounded at 18.2% annually over 10 years.
Pfizer (PFIZER)
Revenue of ₹2,454 Cr in FY2025.
Natural Capsule (NATCAPSUQ)
Revenue of ₹170 Cr in FY2025.